不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.
Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在本研究中,我们通过基因组分析探索了 GI-NKTCL,并确定了 GI-NKTCL 患者中最常见的突变基因(RETSAT 和 SNRNP70)以及通路突变(G2M 检查点和 E2F 靶点)。
结外NK/T细胞淋巴瘤(NKTCL)最常见的鼻外受累部位之一是胃肠道,但胃肠道NKTCL(GI-NKTCL)的报道很少。为深入认识这一表现,本研究回顾性分析GI-NKTCL的临床特征、基因组改变及免疫浸润。
收集2010至2020年在中山大学附属第六医院诊断的GI-NKTCL患者,并通过全外显子组测序获取突变数据。
15例GI-NKTCL患者中,最常见的驱动突变为ARID1B、ERBB3、POT1和TP53(各2/15,14%)。最常见的基因突变为RETSAT(4/15,29%)和SNRNP70(3/15,21%);常见的特征通路突变包括G2M检查点(10/15,66.7%)、E2F靶基因(8/15,53.3%)、雌激素反应晚期和早期、凋亡以及TNFA经NF-κB信号传导(后三者各7/15,46.7%)。在ICIs-Miao队列中,SNRNP7野生型黑色素瘤患者OS显著长于突变型患者。在TCGA-UCEC队列中,RETSAT或SNRNP7突变患者免疫检查点分子表达显著升高,炎症性免疫细胞上调。
本研究通过基因组分析探讨GI-NKTCL,确定了患者中常见的突变基因(RETSAT和SNRNP70)及通路(G2M检查点和E2F靶基因),并分析了常见突变基因与免疫浸润的关联。研究者希望这些基因组改变有助于发现GI-NKTCL的新生物标志物和治疗靶点,并为改善患者治疗与预后提供理论依据。
One of the most common nasal external sites in extranodal Natural Killer/T-cell lymphoma (NKTCL) is in the gastrointestinal (GI) system. Despite this, reports on gastrointestinal-Natural Killer/T-cell lymphoma (GI-NKTCL) are very few. To obtain a better understanding of this manifestation of NKTCL, we conducted a retrospective study on GI-NKTCL to analyze its clinical features, genomic changes and immune infiltration.
We retrospectively collected patients diagnosed with GI-NKTCL in the Sixth Affiliated Hospital of Sun Yat-sen University from 2010 to 2020. From this cohort we obtained mutation data via whole exome sequencing.
Genomic analysis from 15 patients with GI-NKTCL showed that the most common driving mutations were ARID1B(14%, 2/15), ERBB3(14%, 2/15), POT1(14%, 2/15), and TP53(14%, 2/15). In addition, we found the most common gene mutation in patients with GI-NKTCL to be RETSAT(29%, 4/15) and SNRNP70(21%, 3/15), and the most common hallmark pathway mutations to be G2M checkpoint pathway (10/15, 66.7%), E2F targets (8/15, 53.3%), estrogen response late (7/15, 46.7%), estrogen response early (7/15, 46.7%), apoptosis (7/15, 46.7%) and TNFA signaling via NFKB (7/15, 46.7%). In the ICIs-Miao cohort, SNRNP7-wild-type (WT) melanoma patients had significantly prolonged overall survival (OS) time compared with SNRNP7 mutant type (MT) melanoma patients. In the TCGA-UCEC cohort, the patients with RETSAT-MT or SNRNP7-MT had significantly increased expression of immune checkpoint molecules and upregulation of inflammatory immune cells.
In this study, we explored GI-NKTCL by means of genomic analysis, and identified the most common mutant genes (RETSAT and SNRNP70), pathway mutations (G2M checkpoint and E2F targets) in GI-NKTCL patients. Also, we explored the association between the common mutant genes and immune infiltration. Our aim is that our exploration of these genomic changes will aid in the discovery of new biomarkers and therapeutic targets for those with GI-NKTCL, and finally provide a theoretical basis for improving the treatment and prognosis of patients with GI-NKTCL.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。